Home > News > Altair's Thin Coating
April 27th, 2007
Altair's Thin Coating
A few weeks ago, I wrote about how Behr's Premium Plus Ultra paint now uses Nanophase Technologies' (Nasdaq: NANX) proprietary nanoparticles. That news makes the $134 million nanotech company look like a solid, if not spectacular, investment.
You might think I'd be similarly bullish about word from Altair Nanotechnologies (Nasdaq: ALTI) that it's teamed up with leading paint manufacturer Sherwin-Williams (NYSE: SHW) to form a new company, AlSher Titania. All things being equal, it would be a step in the right direction for Altair; but as I've often said before, when it comes to this company, all things are not equal.
First off, Altair claims that AlSher Titania will be able to produce titanium dioxide pigment at a significantly lower price point than rivals. I find this a little hard to believe, especially since BASF (NYSE: BF) and Millennium Chemical (a subsidiary of the Lyondell Company (NYSE: LYO) are among the largest producers of titanium dioxide. On relative economies of scale alone, it's difficult to imagine how Altair's small manufacturing facility could match these behemoths on cost.
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014
Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014
Nanometrics Announces Upcoming Investor Events July 22nd, 2014
Iranian Scientists Produce Cobalt–Alumina Ceramic Nano Inks August 1st, 2014
Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014
Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014
Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014